{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:14:18Z","timestamp":1793387658657,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.advms.2025.10.003","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T19:05:41Z","timestamp":1761678341000},"page":"436-443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The role of sclerostin in the development and progression of cardiovascular diseases- a potential biomarker?"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0617-6513","authenticated-orcid":false,"given":"Sebastian","family":"Stelmaszek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Tarasiuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4517-1498","authenticated-orcid":false,"given":"Remigiusz","family":"Kazimierczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lisowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.advms.2025.10.003_bib1","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"4","key":"10.1016\/j.advms.2025.10.003_bib2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.17772\/gp\/2079","article-title":"Rola szlaku sygna\u0142owego Wnt\/\u03b2-katenina oraz bia\u0142ka LRPS w metabolizmie tkanki kostnej oraz etiologii osteoporozy [The role of Wnt\/\u03b2-catenin pathway and LRP5 protein in metabolism of bone tissue and osteoporosis etiology]","volume":"86","author":"Wolski","year":"2015","journal-title":"Ginekol Pol"},{"issue":"23","key":"10.1016\/j.advms.2025.10.003_bib3","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J"},{"issue":"3","key":"10.1016\/j.advms.2025.10.003_bib4","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1161\/ATVBAHA.116.308723","article-title":"Wnt signaling pathway inhibitor sclerostin inhibits angiotensin II-Induced aortic aneurysm and atherosclerosis","volume":"37","author":"Krishna","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.advms.2025.10.003_bib5","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41569-022-00718-5","article-title":"Non-canonical WNT signalling in cardiovascular disease: mechanisms and therapeutic implications","volume":"19","author":"Akoumianakis","year":"2022","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"10.1016\/j.advms.2025.10.003_bib6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.athoracsur.2020.08.068","article-title":"Wnt signaling mediates pro-fibrogenic activity in human aortic valve interstitial cells","volume":"112","author":"Jarrett","year":"2021","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"10.1016\/j.advms.2025.10.003_bib7","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1038\/s41467-022-31997-8","article-title":"Targeting loop3 of sclerostin preserves its cardiovascular protective action and promotes bone formation","volume":"13","author":"Yu","year":"2022","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.advms.2025.10.003_bib8","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s40520-019-01393-2","article-title":"Serum sclerostin and adverse outcomes in elderly patients with stable coronary artery disease undergoing percutaneous coronary intervention","volume":"32","author":"He","year":"2020","journal-title":"Aging ClinExp Res"},{"issue":"8","key":"10.1016\/j.advms.2025.10.003_bib9","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1210\/jc.2013-1521","article-title":"Sclerostin: another vascular calcification inhibitor?","volume":"98","author":"Claes","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.advms.2025.10.003_bib10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/ckj\/sfv077","article-title":"Independent association between serum sclerostin levels and carotid artery atherosclerosis in prevalent haemodialysis patients","volume":"8","author":"Kirkpantur","year":"2015","journal-title":"Clin Kidney J"},{"issue":"5","key":"10.1016\/j.advms.2025.10.003_bib11","doi-asserted-by":"crossref","first-page":"H1037","DOI":"10.1152\/ajpheart.00355.2022","article-title":"Sclerostin ablation prevents aortic valve stenosis in mice","volume":"323","author":"Joll","year":"2022","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.advms.2025.10.003_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-25651-y","article-title":"Sclerostin as a biomarker of cardiovascular risk in women with systemic lupus erythematosus","volume":"12","author":"Garcia-de los R\u00edos","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.advms.2025.10.003_bib13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/jbmr.4467","article-title":"Circulating sclerostin levels are positively related to coronary artery disease severity and related risk factors","volume":"37","author":"Frysz","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.advms.2025.10.003_bib14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5414\/CN109333","article-title":"Sclerostin is not associated with cardiovascular event or fracture in kidney transplantation candidates","volume":"90","author":"J\u00f8rgensen","year":"2018","journal-title":"Clin Nephrol"},{"issue":"1","key":"10.1016\/j.advms.2025.10.003_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12872-022-02654-1","article-title":"Association of serum sclerostin and osteoprotegerin levels with the presence, severity and prognosis in patients with acute myocardial infarction","volume":"22","author":"Shui","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"issue":"3","key":"10.1016\/j.advms.2025.10.003_bib16","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0002-9149(83)80105-2","article-title":"A more meaningful scoring system for determining the severity of coronary heart disease","volume":"51","author":"Gensini","year":"1983","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.advms.2025.10.003_bib17","first-page":"302","article-title":"Implication of osteoprotegerin and sclerostin in axial spondyloarthritis cardiovascular disease: study of 163 Spanish patients","volume":"36","author":"Genre","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"16","key":"10.1016\/j.advms.2025.10.003_bib18","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.2217\/bmm-2021-0168","article-title":"Low vitamin K status, high sclerostin and mortality risk of stable coronary heart disease patients","volume":"15","author":"Mayer","year":"2021","journal-title":"Biomark Med"},{"issue":"7","key":"10.1016\/j.advms.2025.10.003_bib19","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s11255-020-02495-x","article-title":"The relationship between sclerostin and carotid artery atherosclerosis in patients with stage 3-5 chronic kidney disease","volume":"52","author":"Zhao","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.advms.2025.10.003_bib20","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9208634","article-title":"Circulating miRNA-29b and sclerostin levels correlate with coronary artery calcification and cardiovascular events in maintenance hemodialysis patients","volume":"2021","author":"He","year":"2021","journal-title":"Cardiol Res Pract"},{"issue":"8","key":"10.1016\/j.advms.2025.10.003_bib21","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jdiacomp.2019.04.012","article-title":"Serum sclerostin level and its relation to subclinical atherosclerosis in subjects with type 2 diabetes","volume":"33","author":"Shalash","year":"2019","journal-title":"J Diabet Complicat"},{"key":"10.1016\/j.advms.2025.10.003_bib22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/1471-2369-14-219","article-title":"Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study","volume":"14","author":"Brandenburg","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.advms.2025.10.003_bib23","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.bone.2015.11.008","article-title":"Lower uncarboxylated osteocalcin and higher sclerostin levels are significantly associated with coronary artery disease","volume":"83","author":"Kim","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.advms.2025.10.003_bib24","doi-asserted-by":"crossref","unstructured":"Kanbay M, Siriopol D, Saglam M, Kurt YG, Gok M, Cetinkaya H, et al. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endocrinol Metab. 204;99(10):E1854-E1861. https:\/\/doi.org\/10.1210\/jc.2014-2042.","DOI":"10.1210\/jc.2014-2042"},{"issue":"4","key":"10.1016\/j.advms.2025.10.003_bib25","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/ckj\/sfaa069","article-title":"Associations of serum sclerostin and Dickkopf-related protein-1 proteins with future cardiovascular events and mortality in haemodialysis patients: a prospective cohort study","volume":"14","author":"Stavrinou","year":"2020","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.advms.2025.10.003_bib26","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12882-018-1046-7","article-title":"Associations of sclerostin with carotid artery atherosclerosis and all-cause mortality in Chinese patients undergoing maintenance hemodialysis","volume":"19","author":"Chen","year":"2018","journal-title":"BMC Nephrol"},{"issue":"11","key":"10.1016\/j.advms.2025.10.003_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206761","article-title":"Serum sclerostin and irisin as predictive markers for atherosclerosis in Egyptian type II diabetic female patients: a case control study","volume":"13","author":"Saadeldin","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.advms.2025.10.003_bib28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/nep.12813","article-title":"Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3-5D","volume":"22","author":"Wang","year":"2017","journal-title":"Nephrology (Carlton)"},{"issue":"2","key":"10.1016\/j.advms.2025.10.003_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00223-021-00910-8","article-title":"The role of bone volume, FGF23 and sclerostin in calcifications and mortality; a cohort study in CKD stage 5 patients","volume":"110","author":"Ferreira","year":"2022","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"10.1016\/j.advms.2025.10.003_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199504","article-title":"Circulating levels of sclerostin are associated with cardiovascular mortality","volume":"13","author":"Novo-Rodr\u00edguez","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.advms.2025.10.003_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/5584_2015_202","article-title":"Sclerostin in obstructive sleep apnea","volume":"910","author":"Kosacka","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"10.1016\/j.advms.2025.10.003_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258284","article-title":"Low bone turnover is associated with plain X-ray vascular calcification in predialysis patients","volume":"16","author":"Neto","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.advms.2025.10.003_bib33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cca.2015.10.031","article-title":"Association of bone-derived biomarkers with vascular calcification in chronic hemodialysis patients","volume":"452","author":"Lee","year":"2016","journal-title":"Clin Chim Acta"},{"issue":"4","key":"10.1016\/j.advms.2025.10.003_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.33549\/physiolres.934034","article-title":"Sclerostin levels predict cardiovascular mortality in long-term hemodialysis patients: a prospective observational cohort study","volume":"68","author":"Kalousov\u00e1","year":"2019","journal-title":"Physiol Res"},{"key":"10.1016\/j.advms.2025.10.003_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.atherosclerosis.2016.08.003","article-title":"High serum levels of sclerostin and Dickkopf-1 are associated with acute ischaemic stroke","volume":"253","author":"He","year":"2016","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.advms.2025.10.003_bib36","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s11255-018-1795-z","article-title":"Elevated levels of serum sclerostin are linked to adverse cardiovascular outcomes in peritoneal dialysis patients","volume":"50","author":"Gong","year":"2018","journal-title":"Int Urol Nephrol"},{"issue":"5","key":"10.1016\/j.advms.2025.10.003_bib37","first-page":"2816","article-title":"Serum sclerostin as an independent marker of peripheral artery disease in elderly persons","volume":"11","author":"Teng","year":"2018","journal-title":"Int J Clin Exp Pathol"},{"issue":"3","key":"10.1016\/j.advms.2025.10.003_bib38","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4274\/tjod.galenos.2021.51436","article-title":"Serum sclerostin level and its relation to subclinical atherosclerosis in the polycystic ovary syndrome phenotypes: a prospective controlled study","volume":"18","author":"\u0130ncesu \u00c7intesun","year":"2021","journal-title":"Turk J Obstet Gynecol"},{"issue":"10","key":"10.1016\/j.advms.2025.10.003_bib39","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1007\/s11255-018-1935-5","article-title":"Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder?","volume":"50","author":"Figurek","year":"2018","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"10.1016\/j.advms.2025.10.003_bib40","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-018-0691-2","article-title":"Bone markers and cardiovascular risk in type 2 diabetes patients","volume":"17","author":"Zwakenberg","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.advms.2025.10.003_bib41","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014816","article-title":"Associations of serum Dickkopf-1 and sclerostin with cardiovascular events: results from the prospective bruneck study","volume":"9","author":"Klingenschmid","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"10.1016\/j.advms.2025.10.003_bib42","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/jbmr.4287","article-title":"Sclerostin downregulation globally by naturally occurring genetic variants, or locally in atherosclerotic plaques, does not associate with cardiovascular events in humans","volume":"36","author":"Holdsworth","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"11\u201312","key":"10.1016\/j.advms.2025.10.003_bib43","first-page":"767","article-title":"Serum sclerostin levels and mortality in hemodialysis patients: an 8-Year prospective study","volume":"53","author":"Holdsworth","year":"2022","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1016\/j.advms.2025.10.003_bib44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s12872-022-02654-1","article-title":"Association of serum sclerostin and osteoprotegerin levels with the presence, severity and prognosis in patients with acute myocardial infarction","volume":"22","author":"Shui","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"10.1016\/j.advms.2025.10.003_bib45","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2459\/JCM.0b013e3283561433","article-title":"Serum osteoprotegerin and carotid intima-media thickness in acute\/chronic coronary artery diseases","volume":"14","author":"Ciccone","year":"2013","journal-title":"J Cardiovasc Med (Hagerstown)"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112625000446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112625000446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T16:16:01Z","timestamp":1764605761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1896112625000446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1896112625000446"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2025.10.003","relation":{},"ISSN":["1896-1126"],"issn-type":[{"value":"1896-1126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of sclerostin in the development and progression of cardiovascular diseases- a potential biomarker?","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2025.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Medical University of Bialystok. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}